Table 1.
Exclusion ciriteria
| • |
Previous ERCP |
| • |
Known allergy or intolerance to one of the compounds used in the study |
| • |
Participation in another interventional trial during the previous four weeks |
| • |
Pregnancy and breast feeding |
| • |
current acute pancreatitis |
| • |
Renal insufficiency ≥ stage 4 (K/DOQI), i.e. MDRD-GFR < 30 ml/min/1,73 m2) |
| • |
Hyperthyroidism |
| • |
Symptomatic bradycardia <35 bpm |
| • |
Atrioventricular block > 1° or other cardial conduction defects |
| • |
Myasthenia gravis |
| • |
Liver cirrhosis Child C |
| • |
Overt coagulopathy |
| • |
Kidney stone diathesis (calcium-magnesium-ammonium-phosphate stones) |
| • |
Mental impairment, addiction or other disorders leading to the patients inability to understand the scope and possible consequences of a participation in a clinical trial |
| • |
Magnesium medication within 14 days before the procedure |
| • | Inability to give informed consent |